Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPR3 | P17342 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790384 | 1.00 | NPR3 (0.41) | NPR3ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL789730 | 1.00 | NPR3 (0.41) | NPR3ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL19861842 | 0.86 | FOLH1 (0.35) | NPR3ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL23520088 | 0.86 | FOLH1 (0.35) | NPR3ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL22503353 | 0.86 | NPR3 (0.35) | NPR3ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL20017106 | 0.85 | BIRC2 (0.38) | NPR3ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL22364068 | 0.85 | BIRC2 (0.38) | NPR3ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL22004937 | 0.83 | TAS1R3 (0.47) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL18877136 | 0.83 | NPR3 (0.34) | NPR3ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL18671872 | 0.82 | TDP1 (0.34) | NPR3FOLH1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-11365202-B2 | Antimalarial compounds, process for preparation and their use for drug resistant malaria | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-21 | — | — | US | disclosed |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2021-04-15 | — | — | US | disclosed |
| US-10793591-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV | 2015-01-01 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | NPR3 1695/4885ALDH1A1 1431/4885MEN1 4103/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | NPR3 1695/4885ALDH1A1 1431/4885MEN1 4103/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | NPR3 1695/4885ALDH1A1 1431/4885MEN1 4103/4885 |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | NPR3 1659/4885ALDH1A1 3576/4885MEN1 3489/4885 |
| US-11365202-B2 | Antimalarial compounds, process for preparation and their use for drug resistant malaria | DPP4, DPP7, DPP9 | NPR3 3521/4885ALDH1A1 391/4885MEN1 2347/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | NPR3 1659/4885ALDH1A1 3576/4885MEN1 3489/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | NPR3 2947/4885ALDH1A1 2567/4885MEN1 1839/4885 |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | NPR3 1659/4885ALDH1A1 3576/4885MEN1 3489/4885 |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | NPR3 1659/4885ALDH1A1 3576/4885MEN1 3489/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | NPR3 2947/4885ALDH1A1 2567/4885MEN1 1839/4885 |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | NPR3 1734/4885ALDH1A1 1173/4885MEN1 3311/4885 |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | NPR3 1695/4885ALDH1A1 1431/4885MEN1 4103/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | NPR3 2249/4885ALDH1A1 2210/4885MEN1 1646/4885 |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | NPR3 1117/4885ALDH1A1 2125/4885MEN1 3432/4885 |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | NPR3 1978/4885ALDH1A1 3169/4885MEN1 3340/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | NPR3 1100/4885ALDH1A1 1153/4885MEN1 4230/4885 |
| US-10793591-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | NPR3 1695/4885ALDH1A1 1431/4885MEN1 4103/4885 |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | NPR3 1117/4885ALDH1A1 2125/4885MEN1 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.